Transgene Biotek Ltd

Transgene Biotek has seen a rise in net sales from 0.06 Cr in Mar'23 to 0.26 Cr in Mar'25, but continues to report negative operating profits, with a loss of -1.13 Cr in Mar'25 and increasing total expenditures of 1.39 Cr. The company faces ongoing financial challenges, reflected in persistent losses before and after tax, and stagnant cash flow from operations.

As of 10-Nov, Transgene Biotek Ltd's stock price is at 3.84, up 9.4% today, but has declined 43.78% year-to-date. Despite recent gains, the stock's performance remains weak compared to the Sensex, which has increased 6.91% this year.

As of 06-Nov, Transgene Biotek Ltd's stock price is Rs 3.36, down 6.15%, and has significantly underperformed the market with a year-to-date decline of 50.81%. Despite increased investor participation, the stock remains in a bearish trend, trading below key moving averages and close to its 52-week low.

As of 04-Nov, Transgene Biotek Ltd's stock price is 3.68, down 3.16%, and has underperformed its sector significantly. The stock is in a bearish trend, trading below all major moving averages, with a year-to-date decline of 46.12%, indicating weak investor sentiment.

Transgene Biotek will announce its results on 14 November 2025.

As of 31-Oct, Transgene Biotek Ltd's stock price is Rs. 3.78, showing a slight recovery after recent declines but has hit a new 52-week low and underperformed significantly against the Sensex over various time frames. Despite a short-term gain and increased investor interest, the stock remains in a bearish trend with a year-to-date decline of 44.66%.

As of 01-October, Transgene Biotek Ltd's stock price is at 4.18, showing a 5.56% increase after two days of decline. Despite recent gains and outperforming its sector, the stock's year-to-date performance is down 38.80%, indicating long-term challenges.

As of 23-Sep, Transgene Biotek Ltd's stock price is at 4.00, having increased by 1.27% recently, but it has significantly underperformed over the year with declines of 41.43% year-to-date and 50.06% over the past year. Despite a recent positive trend, the stock faces pressure in a generally favorable market, evidenced by a sharp drop in delivery volume and a decline of 5.44% over the past week.

As of 22-Sep, Transgene Biotek Ltd's stock price is at 3.95, having increased by 2.86% after two days of decline, but it remains below all key moving averages, indicating a bearish trend. The stock has seen a significant year-over-year decline of 50.56% and underperformed against the Sensex, reflecting ongoing challenges in attracting investor interest.

As of 19-Sep, Transgene Biotek Ltd's stock price is at 3.81, down 3.54% and has fallen 13.01% over the last two days. The stock is trading below all major moving averages and has declined 12.41% in the past month and 44.22% year-to-date, indicating significant underperformance compared to the broader market.

As of 18-Sep, Transgene Biotek Ltd's stock price is declining at 3.95, down 9.82%, and has underperformed its sector. Despite a recent short-term gain of 4.50%, the stock's longer-term performance remains negative, with significant drops over the past month and year.

As of 12-Sep, Transgene Biotek Ltd is priced at 3.81, having increased slightly today but down 3.79% over the past week and 20.46% over the past month. The stock is underperforming compared to the Sensex, which has gained 1.48% in the same period, indicating a bearish trend and reduced investor interest.

As of 11-Sep, Transgene Biotek Ltd is priced at 3.78, down 1.05%, and has significantly underperformed its sector and the broader market, with a year-to-date decline of 44.66%. The stock is in a bearish trend, trading below all major moving averages, and has seen a drastic drop in investor participation.

As of 10-Sep, Transgene Biotek Ltd is priced at 3.82, up 3.52% today, but has declined 18.38% over the past month and 44.07% year-to-date. Despite increased investor interest indicated by a 137.51% rise in delivery volume, the stock remains below key moving averages and has underperformed relative to the benchmark Sensex.

As of 09-Sep, Transgene Biotek Ltd's stock price is at 3.69, down 7.75%, and significantly underperforming compared to its sector and the benchmark Sensex. The stock has declined 45.97% year-to-date and shows a troubling trend in both short-term and long-term performance metrics.

As of 08-Sep, Transgene Biotek Ltd's stock price is at 4.00, up 1.01% today, but has declined 3.61% over the past week and 14.53% over the past month. The stock underperforms its sector and major moving averages, with a significant drop in investor participation indicating waning interest.

As of 05-Sep, Transgene Biotek Ltd's stock price is at 3.96, down 1.25%, and it remains below key moving averages, indicating a bearish trend. Despite a slight weekly increase of 2.06%, the stock has significantly underperformed year-to-date with a decline of 42.02%.

As of 04-Sep, Transgene Biotek Ltd's stock price is at 4.01, up 4.16% today, but it has declined 41.29% year-to-date and 50.98% over the past year, indicating a troubling long-term performance despite recent short-term gains.

As of 03-Sep, Transgene Biotek Ltd is trading at 3.85, reflecting a 2.94% increase today, but has declined 16.30% over the past month and 43.63% year-to-date. Despite trading below all key moving averages, a significant rise in delivery volume indicates renewed investor interest.